{"filing":{"accession_number":"0001104659-26-107500","cik":"0002020932","ticker":"AGMB","company_name":"Agomab Therapeutics NV","form":"6-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"tm2625366d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2020932/000110465926107500/tm2625366d1_6k.htm"},"events":[{"id":33279,"run_id":30596,"accession_number":"0001104659-26-107500","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces positive Phase 1 clinical trial results for AGMB-447 in IPF patients, including favorable safety/tolerability, robust target engagement, and the design and planned initiation of a Phase 2 study (INSPIRIA). While the company is clinical-stage and this represents a material clinical milestone advancing the lead program, it does not fit the discrete event categories (not an earnings release, M\u0026A, executive change, or financial obligation). The disclosure is clearly operational—a clinical development milestone—but the specific type is not enumerated, making `operational_other` the appropriate classification.","company_name":"Agomab Therapeutics NV","ticker":"AGMB","filing_date":"2026-09-14","form":"6-K","submitted_at":null,"items":[{"id":36684,"accession_number":"0001104659-26-107500","item_number":"EX-99.1","item_title":"tm2625366d1_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces positive Phase 1 clinical trial results for AGMB-447 in IPF patients, including favorable safety/tolerability, robust target engagement, and the design and planned initiation of a Phase 2 study (INSPIRIA). While the company is clinical-stage and this represents a material clinical milestone advancing the lead program, it does not fit the discrete event categories (not an earnings release, M\u0026A, executive change, or financial obligation). The disclosure is clearly operational—a clinical development milestone—but the specific type is not enumerated, making `operational_other` the appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-14T20:15:42.115423+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36684,"accession_number":"0001104659-26-107500","item_number":"EX-99.1","item_title":"tm2625366d1_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces positive Phase 1 clinical trial results for AGMB-447 in IPF patients, including favorable safety/tolerability, robust target engagement, and the design and planned initiation of a Phase 2 study (INSPIRIA). While the company is clinical-stage and this represents a material clinical milestone advancing the lead program, it does not fit the discrete event categories (not an earnings release, M\u0026A, executive change, or financial obligation). The disclosure is clearly operational—a clinical development milestone—but the specific type is not enumerated, making `operational_other` the appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-14T20:15:42.115423+00:00","company_name":"Agomab Therapeutics NV","ticker":"AGMB","filing_date":"2026-09-14"}]}